Catalent (STU:0C8) Debt-to-Equity : 1.40 (As of Sep. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Catalent Debt-to-Equity?

Catalent's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €55 Mil. Catalent's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €4,402 Mil. Catalent's Total Stockholders Equity for the quarter that ended in Sep. 2024 was €3,191 Mil. Catalent's debt to equity for the quarter that ended in Sep. 2024 was 1.40.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Catalent's Debt-to-Equity or its related term are showing as below:

STU:0C8' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.76 Med: 1.36 Max: 4.02
Current: 1.4

During the past 13 years, the highest Debt-to-Equity Ratio of Catalent was 4.02. The lowest was 0.76. And the median was 1.36.

STU:0C8's Debt-to-Equity is ranked worse than
91.41% of 827 companies
in the Drug Manufacturers industry
Industry Median: 0.27 vs STU:0C8: 1.40

Catalent Debt-to-Equity Historical Data

The historical data trend for Catalent's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Catalent Debt-to-Equity Chart

Catalent Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Debt-to-Equity

Get a 7-Day Free Trial

0.87

0.76

0.88

1.05

1.37

Catalent Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Equity	Get a 7-Day Free Trial															1.29	1.36	1.38	1.37	1.40

Competitive Comparison of Catalent's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Catalent's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Catalent's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Catalent's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Catalent's Debt-to-Equity falls into.

Catalent Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Catalent's Debt to Equity Ratio for the fiscal year that ended in Jun. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(56.669	+	4512.153)	/	3348.116
	=	1.36

Catalent's Debt to Equity Ratio for the quarter that ended in Sep. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(54.961	+	4402.286)	/	3191.342
	=	1.40

Catalent (STU:0C8) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Catalent Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Catalent's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Catalent Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Catalent Inc (STU:0C8) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

CTLT:USA 0C8:Germany

Address

14 Schoolhouse Road, Somerset, NJ, USA, 08873

Website

https://www.catalent.com

Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.

Catalent Headlines

No Headlines